Back to results
US 2023/0057602 A1Published application
Methods of treatment with antibodies against bcma and cd3
AssigneeBristol-Myers Squibb Company
InventorsMichael BURGESS, Kristen HEGE, Kaushik DATTA, Isaac BOSS, Minh Diem VU
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating a patient having a disorder associated with BCMA expression (e.g. BCMA-expressing B-cell cancers, such as multiple myeloma) using dose-escalation dosing regimens with multispecific (e.g. bispecific) antibodies that bind to CD3 and BCMA.
Claims15
A multispecific antibody that binds to BCMA and CD3, for use in treating a disorder associated with BCMA expression in a patient, wherein the treatment comprises the administration of the multispecific antibody in a dosing regimen comprising:
- (i) a starting phase, wherein one or more starting doses of the multispecific antibody are administered to the patient;
- and
- (ii) a maintenance phase, wherein a first maintenance dose of the multispecific antibody is administered to the patient, optionally followed by at least one additional maintenance dose of the multispecific antibody,
- wherein each maintenance dose is greater than the one or more starting doses.
1 more element
Dependencies are inferred from the claim text.